Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909692 | 0.93 | LMNA (0.52) | LMNAHTR1DGRIN2BSRD5A1FAAH | |
| SCHEMBL10176999 | 0.90 | SRD5A1 (0.44) | LMNAHTR1DGRIN2BSRD5A1KDM4E | |
| SCHEMBL15759171 | 0.90 | SRD5A1 (0.44) | LMNAHTR1DGRIN2BSRD5A1KDM4E | |
| SCHEMBL15759191 | 0.90 | SRD5A1 (0.44) | LMNAHTR1DGRIN2BSRD5A1KDM4E | |
| SCHEMBL15759140 | 0.89 | KDM4E (0.47) | LMNAHTR1DGRIN2BSRD5A1KDM4E | |
| SCHEMBL15759169 | 0.87 | KDM4E (0.46) | GRIN2BSRD5A1KDM4EALDH1A1 | |
| SCHEMBL15759219 | 0.87 | SRD5A1 (0.44) | LMNAHTR1DGRIN2BSRD5A1KDM4E | |
| SCHEMBL20909691 | 0.87 | LMNA (0.52) | LMNAHTR1DGRIN2BSRD5A1FAAH | |
| SCHEMBL13102446 | 0.86 | LMNA (0.44) | LMNAGRIN2BSRD5A1FAAHTSHR | |
| SCHEMBL4148484 | 0.85 | LMNA (0.40) | LMNAHTR1DGRIN2BHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | LMNA 2404/4885HTR1D 2239/4885GRIN2B 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.